over 350 such drug candidates are being evaluated in the clinical stages of development – Roots Analysis

 

Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.

 

To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

 

The report provides a detailed study on the current market landscape and future potential of biologics designed for subcutaneous administration. In addition, the study provides an in-depth analysis of the formulation technologies and drug delivery systems (focusing on large volume wearable injectors, autoinjectors, pen injectors, needle-free injectors, drug reconstitution systems, prefilled syringes and implants) that enable subcutaneous delivery of the biologic drugs. Amongst other elements, the report features the following:

• A detailed assessment of the current market landscape of commercially available and clinical-stage biologics that are designed for delivery via the subcutaneous route
• A case study on leading subcutaneous biologics (in terms of revenues generated), featuring details on mechanism of action, development history, annual sales, technology platform (if available), and a comparison of their intravenous and subcutaneous formulations (if applicable).
• An assessment of the various subcutaneous formulation technologies along with information on developers, type of pharmacological molecule, route of administration, mechanisms of action and primary advantage(s).
• An insightful three-dimensional comparison of the subcutaneous formulation technology developers, based on pipeline strength, supplier power of the developer and primary advantages offered by their respective technologies.
• Elaborate profiles of key technology developers, featuring a brief overview of the company, its technology portfolio, product portfolio, financial information (if available), recent developments and an informed future outlook.
• An analysis of collaborations  and partnership agreements inked by the subcutaneous formulation technology developers since 2011

 

The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:

• Phase of development

• Approved
• Pre-registration & Phase III
• Phase II & Phase II/III

 

• Type of molecule

• Cell and gene therapies
• Monoclonal antibodies
• Proteins
• Peptides (recombinant)
• Vaccines
• Others

 

• Target therapeutic area

• Autoimmune disorders
• Blood disorders
• Bone disorders
• Genetic disorders
• Metabolic disorders
• Neurological disorders
• Oncological disorders
• Respiratory disorders
• Others

 

• Type of drug delivery system
• Large volume wearable injectors
• Autoinjectors
• Prefilled syringes
• Needle-free injectors
• Drug reconstitution systems

 

• Revenues from licensing deals
• Upfront payments
• Milestone payments

 

• Key geographical regions
• North America
• Europe
• Asia Pacific
• Rest of the World

 

The Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030 report features the following companies, which we identified to be key players in this domain:

• Adocia

• Ajinomoto Bio-Pharma Services
• Arecor
• Alteogen
• Ascendis Pharma
• Avadel Pharmaceuticals
• Camurus
• Creative BioMart
• Creative Biolabs
• DURECT
• Eagle Pharmaceuticals
• Halozyme Therapeutics
• MedinCell
• Xeris Pharmaceuticals
• Serina Therapeutics

 

Table of Contents

1. Preface

 

1. Executive Summary

 

1. Introduction

 

1. Subcutaneous Biologics: Current Market Landscape

 

1. Case Study: Leading Subcutaneous Biologics

 

1. Subcutaneous Formulation Technologies: Current Market Landscape

 

1. Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis

 

1. Subcutaneous Formulation Technology Developers: Company Profiles

 

1. Partnerships and Collaborations

 

1. Subcutaneous Drug Delivery Systems: Current Market Landscape

 

1. Swot Analysis

 

1. Market Forecast and Opportunity Analysis

 

1. Concluding Remarks

 

1. Executive Insights

 

1. Appendix 1:  Tabulated Data

 

1. Appendix 2: List Of Companies And Organization

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

+44 (122) 391 1091

[email protected]